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SUMMARY 
Background: Therapeutic drug monitoring (TDM) is essential to ensure that aminoglycoside peak concentrations are 
high enough for effective antimicrobial treatment and trough levels are low enough to minimise toxicity. Inappropriate 
utilisation of TDM may lead to suboptimal therapy, toxicity and waste of resources. This study aimed to investigate 
the standard of aminoglycoside TDM performed in adult hospitalised patients.  
Design: An observational, descriptive, cross-sectional study. 
Setting: A 221-bed private hospital. 
Participants: All patients, older than 18 years, on intravenous aminoglycosides for more than 48 hours were included. 
Interventions: None, was observational. A computerised database and patient files were used to obtain the 
information required for this study. Descriptive statistical analysis was used. 
Main outcomes measures: Aminoglycoside blood levels and estimated glomerular filtration rate (eGFR) in the 
patients.  
Results: One hundred and three (103) patients were included: 65 on gentamicin and 38 on amikacin. Blood levels 
were performed in only 19 gentamicin (29.23%) and 22 amikacin (57.89%) patients. Trough levels were taken more 
than 2 hours before the next dose in 12 gentamicin (63.16%) and 12 amikacin (54.54%) patients. The majority of 
patients (96.92% on gentamicin and 84.21% on amikacin) received once daily doses. TDM was performed in all 
patients with an estimated glomerular filtration rate (eGFR) lower than 60 mL/min/1.73m2 and in 23.31% of 
gentamicin patients and 56.76% of amikacin patients with an eGFR higher than 60 mg/min/1.73m2.   
Conclusions: Incorrect sampling times and unnecessary levels taken in patients with normal renal function indicate a 
need for aminoglycoside treatment guidelines in the private hospital. 
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INTRODUCTION 
Therapeutic drug monitoring (TDM) is defined as the 
measured drug concentration combined with adequate 
medical interpretation to influence the drug therapy in 
patients1 and an important tool in pharmacotherapy. The 
purpose of TDM is to individualise the therapeutic 
regimen of the patient to gain optimal benefit with the 
lowest toxicity. Research has shown blood samples for 
TDM purposes are not always taken correctly and 
protocols do not exist, or are not always followed,2 which 
can lead to incorrect dosing regimens and waste of time 
and resources, especially in developing countries.2  
 
Measurement of aminoglycoside concentrations and 
dosage individualisation should be standard practice for 
all critically ill patients treated with aminoglycosides.3 
 
Aminoglycoside antibiotics are concentration-dependent 
— a higher antibiotic concentration (Cmax) to minimum 
inhibitory concentration (MIC) ratio (Cmax:MIC) will 
exhibit a greater antimicrobial activity. Aminoglycosides 
also exhibit a post-antibiotic effect, meaning that a 
persistent suppression of bacterial growth is 




The hydrophilic nature of aminoglycosides can lead to 
changes in volume of distribution in certain conditions, 
such as sepsis, which can lower peak concentrations and 
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excreted in the kidneys and many critically ill patients 
present with impaired renal function. In patients with 
impaired renal function, two samples (peak and trough) 
are recommended to individualise the regimen by using 
the Sawchuk-Zaske calculations or Bayesian 
approaches.5  
 
Guidelines to perform TDM become even more 
important in Intensive Care Units (ICUs) where the 
weights of the patients may be unknown and their 
pharmacokinetics can change daily. The once daily 
dosing regimen adopted over the past few years is based 
on the assumption that the peak concentration will be 
adequate for most infections and peak levels are not 
routinely requested. There is, however, evidence 
indicating that the length of hospital stay is decreased and 
nephrotoxicity reduced by aminoglycoside dosage 
individualisation in critically ill patients,1,3 therapeutic 
drug monitoring, therefore also improves overall patient 
outcome.  
 
The South African Medicines Formulary (SAMF) 
recommends that trough levels be obtained 48 to 72 hours 
after commencement of therapy, immediately prior to the 
next dose, and dose or interval adjustments made if 
necessary. It also recommends a peak level for effective 
bacterial kill after the second dose. There is limited data 
on TDM of aminoglycosides in South Africa, therefore 
this study was performed to evaluate the standard of this 
service in a private hospital.  
 
METHODS 
Study design and population 
The study was an observational, descriptive, 
retrospective, cross-sectional study conducted in a 221-
bed private hospital located in the Western Cape, South 
Africa. The target population included all patients who 
received gentamicin and amikacin, for longer than 48 
hours, during the research period. The study population 
consisted of all patients, 18 years and older, who received 
aminoglycosides whilst admitted in the hospital during 
the research period from November 2014 to October 
2016. Patients from the emergency centre, or who 
received aminoglycosides as surgical prophylaxis were 
excluded from the study.  
 
The measurements taken were to determine the dosages 
of aminoglycosides prescribed, the percentage of patients 
where drug levels were monitored, the percentage of 
patients with abnormal renal function where TDM was 
done and whether dosages were adjusted in case of drug 
levels outside of the normal range. 
 
Data collection  
Patient files and a computerised database were used to 
collect data at a specific time point. The hospital 
dispensing programme was used to find patient numbers 
for patients who received gentamicin or amikacin 
treatment. Data collected from the patient’s files included 
the patient’s age, gender and weight, the dosage of 
aminoglycoside prescribed and frequency, as well as time 
of day when gentamicin or amikacin were prescribed.  
 
Laboratory reports were used to determine the peak and 
trough levels in cases where blood samples were taken 
for TDM. The laboratory results were also used to 
determine whether the results were within normal 
reference ranges. The following was documented: 
dosages prescribed, patient weight, age and gender, time 
of collection of blood sample, whether the drug levels 
were within reference ranges and patient renal function.  
 
Data analysis 
The statistical analysis was performed using the SPSS 
programme.6 Descriptive statistical analysis was used to 
describe and summarise data. Categorical variables were 
expressed as frequencies and percentages, and 
continuous variables were expressed as mean and 
standard deviations (SDs). 
 
Ethical considerations 
Permission to conduct the study was obtained from the 
Health Research Ethics Committee of North-West 
University (NWU-00363-15-A1). Goodwill permission 
was obtained from the hospital group’s corporate office, 
the hospital manager and manager of the laboratory. 
 
RESULTS 
This study comprised 178 files of patients who received 
aminoglycosides while admitted to the private hospital 
during the study period of 1 November 2014 and 31 
October 2016. Of these, 103 patient files met the 
inclusion criteria. The 75 patients excluded from the 
study either received aminoglycosides as surgical 
prophylaxis, or were treated for less than 48 hours. Sixty-
five patients received gentamicin and 38 amikacin. 
 
Demographic characteristics of the patients 
The demographic characteristics of the patients are 
shown in Table I. Of the 65 patients on gentamicin (mean 
age 57.38 ± 15.16 years), 63.10% (n=41) were males. 
Patients on amikacin were marginally younger at 54.29 
±22.85 years (Cohen’s d = 0.14) and of these, 60.53% 
(n=23) were males.  
 
Only two patients on gentamicin had an estimated 
glomerular filtration rate (eGFR) of lower than 60 
mL/min/1.73m2, compared to one patient on amikacin.  
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55.26% in the amikacin group, had eGFR values higher 
than 90 mg/min/1.73m2. 
 
Table I Patient demographics 
 Gentamicin 
(N = 65) 
Amikacin 
(N = 38) 
Age (years), mean ± SD 57.38 ± 15.16 54.29 ± 22.85 
Gender, n (%)   
Male 41 (63.10) 23 (60.53) 
Female 24 (36.90) 15 (39.47) 
Renal function (eGFR) n(%) 
< 60 mL/min/1.73m2 2 (3.08) 1 (2.63) 
60-90 mL/min/1.73m2 15 (23.08) 15 (39.48) 
> 90 mL/min/1.73m2 43 (66.15) 21 (55.26) 
Renal function not tested 5 (7.69) 1 (2.63) 
 
Table 2 Dosage and blood level results for the patients 





240 mg/day 38 (58.5) n/a 
160 mg/day 10 (15.4 n/a 
400 mg/day 7 (10.8) n/a 
180 mg/day 5 (7.7) n/a 
320 mg/day 2 (3.1) n/a 
80 mg 8-hourly 2 (3.1) n/a 
480 mg/day 4 (1.5) n/a 
1000 mg/day n/a 30 (78.95) 
500 mg 12-hourly n/a 5 (13.16) 
750 mg/day n/a 2 (5.26) 
1000 mg 12-hourly n/a 1 (2.63) 
TDM results   
<1 mg/L 13 (20.00) n/a 
>1 mg/L 6 (9.23) n/a 
<5 mg/L n/a 19 (50.00) 
>5 mg/L n/a 3 (7.89) 
No TDM done 46 (70.77) 16 (42.11) 
TDM for eGFR< 60 mL/min/1.73m2 
TDM done 2 (100) 1 (100) 
TDM not done 0 1 
TDM for eGFR> 60 mL/min/1.73m2 
TDM done 17 (29.31) 21 (56.76) 
TDM not done 41 (70.69) 16 (43.24) 
TDM done where eGFR not tested 
TDM done 0 0 
TDM not done 5 (100) 0 
Sampling times   
0-1 hour before next dose 1 (5.26) 5 (22.73) 
1-2 hours before next dose 6 (31.58) 5 (22.73) 
> 2 hours before next dose 12 (63.16) 12 (54.54) 
TDM = Therapeutic drug monitoring 
n/a = Dosage range not applicable to specific drug 
 
Dosages and blood level results of the patients 
Table 2 shows the dosages and blood level results 
according to ideal trough level concentrations and renal 
functions, and sampling times for patients on gentamicin 
and amikacin, respectively.  
The sampling time refers to the time when blood was 
drawn to measure aminoglycoside levels. In all patients, 
levels taken were trough levels. 
 
Only two patients (3.08%) on gentamicin received an 
eight-hourly dose, 63 patients received a once daily dose 
and 38 (60.32%) received a dose of 240 mg daily, see 
table 3. Blood levels were drawn in only 19 (29.23%) of 
the patients and 13 levels were lower than 1 mg/L and six 
levels higher than 1mg/L. Therapeutic drug monitoring 
was performed in both patients with a renal function of 
lower than 60 mL/min/1.73m². The renal function was 
higher than 60 mL/min/1.73m2 in 17(89.47%) patients on 
gentamicin where TDM was performed. 
 
Table 3 Dosage and blood level results for the patients 





240 mg/day 38 (58.5) n/a 
160 mg/day 10 (15.4 n/a 
400 mg/day 7 (10.8) n/a 
180 mg/day 5 (7.7) n/a 
320 mg/day 2 (3.1) n/a 
80 mg 8-hourly 2 (3.1) n/a 
480 mg/day 4 (1.5) n/a 
1000 mg/day n/a 30 (78.95) 
500 mg 12-hourly n/a 5 (13.16) 
750 mg/day n/a 2 (5.26) 
1000 mg 12-hourly n/a 1 (2.63) 
TDM results 
<1 mg/L 13 (20.00) n/a 
>1 mg/L 6 (9.23) n/a 
<5 mg/L n/a 19 (50.00) 
>5 mg/L n/a 3 (7.89) 
No TDM done 46 (70.77) 16 (42.11) 
TDM for eGFR< 60 mL/min/1.73m2 
TDM done 2 (100) 1 (100) 
TDM not done 0 1 
TDM for eGFR> 60 mL/min/1.73m2 
TDM done 17 (29.31) 21 (56.76) 
TDM not done 41 (70.69) 16 (43.24) 
TDM done where eGFR not tested 
TDM done 0 0 
TDM not done 5 (100) 0 
Sampling times   
0-1 hour before next dose 1 (5.26) 5 (22.73) 
1-2 hours before next dose 6 (31.58) 5 (22.73) 
> 2 hours before next dose 12 (63.16) 12 (54.54) 
TDM = Therapeutic drug monitoring 
n/a = Dosage range not applicable to specific drug 
 
In the amikacin group, six patients (N = 38) received a 
12-hourly dose and 30 (78.95%) patients received a dose 
of 1000 mg daily. Blood levels were drawn in 22 
(57.89%) of the patients and 19 levels were lower than 5 
mg/L and three were higher than 5 mg/L. Therapeutic 
drug monitoring was performed for the one patient on 
amikacin with a renal function lower than 60 
mL/min/1.73m².  
DISCUSSION 
To our knowledge, this was the first study where the 
standard of therapeutic drug monitoring of 
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investigated in a private hospital in the Western Cape, 
South Africa, and resulted in a number of key findings. 
Firstly, in this study the male to female ratio was the same 
for gentamicin and amikacin groups, with approximately 
60% males and 40% females.  
 
It is important to remember that this is a general hospital 
and the study only investigated the patients on 
aminoglycosides, therefore it is not a reflection of all the 
patients admitted to the hospital. Kushner et al., 2016,7 
reported a higher percentage of women on gentamicin in 
patients younger than 50 years.  
 
Interestingly, in the population older than 55 years, the 
same age as the patients in this study, the usage of 
gentamicin was comparable with the results of this study. 
Secondly, we found that approximately 97% of patients 
in the gentamicin group and 84% in the amikacin group 
received once-daily doses of the drug, which is in line 
with literature recommendations for treatment8, as well 
as the South African guidelines for the use of 
aminoglycosides.9 In a survey performed in 2015 by 
Tabah et al., 94% of patients received once-daily doses 
of gentamicin and amikacin.10  
 
Once daily dosing of aminoglycosides is associated with 
similar efficacy, but with fewer adverse effects due to the 
concentration dependent nature of the drug.11 Thirdly, we 
determined that trough levels only were performed for 
29.23% of patients on gentamicin and 57.89% on 
amikacin treatment. The higher percentage of trough 
level measurements with amikacin compared to 
gentamicin needs further exploration. Although 
nephrotoxicity is an adverse effect with all 
aminoglycosides, literature indicates that gentamicin 
concentrate in the kidneys to a higher degree than the 
other aminoglycosides and therefore more prone to 
toxicity than amikacin.12 
 
Trough levels are sufficient to determine the likelihood 
of adverse effects, but to calculate individual doses per 
patient to optimise treatment, it is necessary to measure 
both trough and peak levels. With these calculations, it 
can be ensured the desired MIC for the organism is 
reached, and trough levels are below threshold levels to 
prevent adverse effects.13 Peak levels become very 
important in critically ill patients with abnormal 




When individualised patient dosages are calculated by 
measuring peak and trough levels, a greater percentage of 
patients will achieve the targeted concentration compared 
to those who receive fixed doses. Improved clinical 
outcomes are achieved in patients who attained targeted 
therapeutic serum concentrations early in treatment.4 To 
ensure optimal treatment of organisms, it is suggested 
that a Cmax/MIC ratio of 8 to 10 is achieved. Whether this 
is the case in individual patients can only be determined 
if a peak level is measured.3  
 
In patients with abnormal renal function (renal 
insufficiency) it is of utmost importance to take two 
levels to determine true peak and trough levels and 
individualise treatment for each patient; this has not been 
necessary in our study. This could lead to treatment 
failure in infections caused by organisms with higher 
MIC, because the peak level is not measured and not 
known to be 8 to 10 times the MIC. In critically ill 
patients, a peak and trough level can be used to 
individualise dosages and ensure optimal treatment.3 
 
Fourthly, sampling time was not consistently within one 
hour before administration of the next dose. Of the six 
patients (9.23%) in the gentamicin group, where the 
gentamicin levels were > 1 mg/L, none of the samples 
was taken within one hour before administration of the 
next dose. In the amikacin group, there were three cases 
where the amikacin levels were > 5 mg/L, and none of 
these was taken within one hour before administration of 
the next dose; of these values, none are therefore reliable 
and true trough levels.  
 
Trough levels should be measured within one hour before 
the next dose and the peak levels 30 minutes after 
completing the intravenous injection.14 Incorrect 
sampling time will lead to incorrect trough levels, as 
actual levels just before administration of the next dose 
will be lower than the levels measured more than two 
hours earlier. A trough level, without the knowledge of 
the time sampled, can be mistaken for toxicity.   
 
The South African Department of Health’s guidelines 
suggest that trough levels for amikacin and gentamicin be 
measured three times per week in haemodynamically 
stable patients.9 In our study, TDM was performed in all 
patients with eGFR< 60 mL/min/1.73m², but in patients 
with eGFR> 60 mL/min/1.73m² it seems that TDM were 
done randomly and no pattern of practice could be found. 
In the gentamicin group, TDM was performed for 
29.13% of patients with eGFR> 60 mL/min/1.73m2 and 




In the gentamicin group, there were five patients where 
eGFR was not tested at all and no TDM was done either. 
Similar results were found in a study by Al Za’abi et al., 
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their results to incorrect sampling times and the lack of 
policy.2 Active TDM strategies (performed according to 
policy for all patients and not only when prescribed by 
the medical practitioner) result in reduced nephrotoxicity 
as well as a shorter hospital stay.3 Finally, we found that 
dosages were not calculated per patient according to 
weight. This might be because many of the patients were 
in ICU and could not be weighed.  
 
Limitations of this study 
This study reflects only the situation in a private hospital 
in South Africa and does not indicate the standard of 
TDM practices in other private or public hospitals in the 
country. As only retrospective data were used, the patient 
outcomes could not be determined. All information 
required to determine the standard of TDM in the private 
hospital was not available, as many patient’s weights 
were not recorded in patient charts. 
 
CONCLUSION 
The study has shown that aminoglycoside levels are 
drawn, but the results are underutilised due to the lack of 
clear TDM guidelines. In this small population, most of 
the patients had normal renal function and most of the 
trough levels were within the recommended range, 
although levels were not always taken at the correct times 
and sample times were not always documented.  
 
Hospital policy, in line with international TDM 
guidelines, can improve therapy and reduce the 
probability of toxicity, especially in patients with 
unstable or impaired renal function. The policy can also 
include peak levels in patients with resistant organisms 
and compromised pharmacokinetics to individualise 
therapy even further. 
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